NCT00003079View on ClinicalTrials.gov

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

May 31, 2001

Study Completion Date

May 31, 2001

Conditions
LeukemiaLymphoma
Interventions
DRUG

bryostatin 1

DRUG

cytarabine

Trial Locations (3)

10021

New York Presbyterian Hospital - Cornell Campus, New York

77030

University of Texas - MD Anderson Cancer Center, Houston

23298-0037

Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT00003079 - Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma | Biotech Hunter | Biotech Hunter